Scinai Immunotherapeutics (SCNI) files Form 6-K with H1 2025 update

Rhea-AI Filing Summary

Scinai Immunotherapeutics Ltd. submitted a Form 6-K providing a business update for the first half of 2025. The filing includes a press release, condensed interim unaudited financial statements, and an operating and financial review and prospects, each as of June 30, 2025.

The company also states that this Form 6-K, including these exhibits, is incorporated by reference into its existing registration statements on Form S-8 and Form F-3. This links the new interim information directly into Scinai’s previously filed securities registration documents.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of September 2025

Commission File Number: 001-37353

SCINAI IMMUNOTHERAPEUTICS LTD.

(Translation of registrant’s name into English)

Jerusalem BioPark, 2nd Floor

Hadassah Ein Kerem Campus

Jerusalem, Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

EXPLANATORY NOTE 

Attached are the Company’s press release providing a business update for the first half of 2025, condensed interim unaudited financial statements and a summary of its operating and financial review and prospects, each as of June 30, 2025, furnished herewith as Exhibits 99.1, 99.2 and 99.3, respectively

This Report on Form 6-K (including Exhibits 99.1, 99.2 and 99.3) is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-271293 and File No. 333-239344) and Form F-3 (File No. 333-274078 and File No. 333-276767), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

Exhibit Index

Exhibit No.		Description
99.1		Press Release dated September 2, 2025
99.2		Condensed Consolidated Unaudited Financial Statements as of June 30, 2025
99.3		Operating and Financial Review and Prospects as of June 30, 2025
101.INS		Inline XBRL Instance Document
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Label Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Presentation Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Definition Linkbase Document
104		Cover Page Interactive Data File formatted as Inline XBRL and contained in Exhibit 101

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Scinai Immunotherapeutics Ltd.
Date: September 2, 2025	By:	/s/ Amir Reichman
		Amir Reichman
		Chief Executive Officer

2

FAQ

What does Scinai Immunotherapeutics (SCNI) disclose in this Form 6-K?

Scinai Immunotherapeutics provides a business update for the first half of 2025, including a press release, condensed interim unaudited financial statements, and an operating and financial review and prospects as of June 30, 2025.

Which financial statements are included in Scinai Immunotherapeutics’ June 30, 2025 Form 6-K?

The Form 6-K includes condensed consolidated unaudited financial statements as of June 30, 2025. These are accompanied by an operating and financial review and prospects that further explain the company’s results and outlook for that period.

How is this Scinai Immunotherapeutics (SCNI) Form 6-K used in its registration statements?

Scinai states that this Form 6-K, including Exhibits 99.1, 99.2 and 99.3, is incorporated by reference into its Form S-8 and Form F-3 registration statements, making the June 30, 2025 information part of those filings.

What exhibits accompany Scinai Immunotherapeutics’ September 2025 Form 6-K?

The exhibits include a September 2, 2025 press release, condensed consolidated unaudited financial statements as of June 30, 2025, and an operating and financial review and prospects, along with various Inline XBRL data files and the cover page interactive data file.

Who signed Scinai Immunotherapeutics’ September 2, 2025 Form 6-K?

The Form 6-K was signed on behalf of Scinai Immunotherapeutics Ltd. by Amir Reichman, the company’s Chief Executive Officer, dated September 2, 2025, confirming the company’s authorization of the submission.

What period does Scinai Immunotherapeutics’ business update in this Form 6-K cover?

The business update, financial statements, and operating and financial review included with the Form 6-K all relate to Scinai Immunotherapeutics’ position as of June 30, 2025, covering the first half of 2025.